BioFire Diagnostics has received an additional $20 million investment from Athyrium Opportunities Fund, increasing the amount of funding from the group to $45 million. The company said it will use the new funding to further commercialize its FilmArray molecular diagnostic platform. The platform's FilmArray Respiratory Panel can detect 17 viral and three bacterial targets. The company said it is also seeing progress with the product's other panels, including one for sepsis.
Published in Brief: